SEC Filing Summary: Alphabet Inc. (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. for the reporting period ending September 30, 2025. The document discloses equity securities held by the company that are reportable under the Securities Exchange Act of 1934. It does not contain Alphabet's own financial performance data (revenue, profit, or cash flow) but rather details its investment portfolio in other public companies.
Key Financial Metrics and Portfolio Composition
The filing lists specific equity holdings with their respective values, share counts, and voting authority. Key observations include:
- Portfolio Scope: The table includes holdings in various sectors, with a notable concentration in biotechnology, healthcare, and technology software.
- Top Holdings by Value:
- Planet Labs PBC: 31,942,641 shares valued at approximately $414.6 million.
- AST SpaceMobile Inc: 8,943,486 shares valued at approximately $438.9 million.
- Arm Holdings PLC: 1,960,784 shares valued at approximately $277.4 million.
- Prime Medicine Inc: 16,562,498 shares valued at approximately $91.8 million.
- UiPath Inc: 7,034,337 shares valued at approximately $94.1 million.
- Voting Authority: Alphabet reports "Sole" voting authority for the majority of these positions, with some instances of "Shared" or "None" authority noted in specific rows.
Material Changes and Comparisons
The provided text contains only the snapshot of holdings as of September 30, 2025. It does not include comparative data from the prior quarter (June 30, 2025) or year-over-year figures. Therefore, material changes in position size or new/liquidated positions cannot be determined from this specific input text alone.
Guidance, Outlook, and Risks
Guidance and Outlook: This filing type does not contain management commentary, forward-looking guidance, or strategic outlook for Alphabet Inc. or the underlying portfolio companies.
Risks and Contingencies: The filing includes a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness. No specific risk factors or contingencies regarding the investments are detailed in the provided text.
Investor Verification Checklist
- Portfolio Concentration: Verify the total aggregate value of these holdings against Alphabet's total assets to assess the significance of this investment portfolio.
- Quarterly Flows: Compare this list against the Q2 2025 13F filing to identify new entries (e.g., specific biotech firms) or exits.
- Voting Rights: Review the "Voting Authority" column to understand Alphabet's level of influence over the governance of these portfolio companies.
- Valuation Accuracy: Confirm that the "Value" column reflects the fair market value at the period end, as required by SEC regulations.